Stock comparison
Halozyme Therapeutics
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 75B | HALO |
| Benjamin Graham | 83A | 80A | HALO |
| Philip Fisher | 65B | 75B | IDXX |
| Peter Lynch | 53D | 71B | IDXX |
| Joel Greenblatt | 40D | 83C | IDXX |
| Charlie Munger | 80C | 87A | IDXX |
| Terry Smith | 84A | 84A | Tie |
Side-by-side metrics
| Metric | HALO | IDXX |
|---|---|---|
| Market cap | $8.1B | $44.06B |
| P/E (TTM) | 24.0x | 39.0x |
| EV/EBIT | 10.2x | 31.6x |
| ROIC (TTM) | 23.65% | 40.66% |
| Gross margin | 81.24% | 62.05% |
| Net margin | 23.13% | 24.63% |
| Revenue CAGR 5y | 33.23% | 7.56% |
| EPS CAGR 5y | -1.98% | 10.79% |
| Debt / Equity | 1.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 7.56%+77%
- EV/EBIT10.2xvs 31.6x+68%
- P/E (TTM)24.0xvs 39.0x+38%
- Gross margin81.24%vs 62.05%+24%
IDXX leads on
- EPS CAGR 5y10.79%vs -1.98%+118%
- Market cap$44.06Bvs $8.1B+82%
- ROIC (TTM)40.66%vs 23.65%+42%
- Debt / Equity0.7xvs 1.0x+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.